跳至主要内容
临床试验/NCT00646945
NCT00646945已完成4 期

International, Randomized, Controled, Double-Blind Study Assessing Efficacy of Kalinox® 170 Bar During the Realization of Invasive Gestures in Adult Oncology

Air Liquide Santé International1 个研究点 分布在 1 个国家目标入组 204 人开始时间: 2007年9月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
204
试验地点
1
主要终点
pain measurement with visual analogue scale

研究概览

简要总结

In the oncology practice, The National Union of the Centres of Fight Against the Cancer recently published the Standards, Options and Recommendations for the coverage of the pains provoked during the invasive gestures of a short duration realized at patients affected by cancer. These support the use of the Kalinox ® 170 bar as therapeutic alternative for the preparation of the painful procedures of a short duration such as spinal taps or osseous at the adult.The objective of this study thus is to clarify the appropriate efficiency and the tolerance of the equimolar mixture protoxide of nitrogen / oxygen during invasive procedures realized in adult oncology with regard to the analgesic reference methods and to the effect placebo leads by the accompaniment of the patient during the procedure.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age > 18 year
  • OMS between 0 to 3
  • Patient who has to undergo an invasive gesture or a painful care
  • Absence of contra-indication to the administration of the product

排除标准

  • Patient already included in another incompatible study with this protocol
  • Patient incapable of self-assessment by the EVA
  • Confusional syndrome
  • Patient already included in this protocol
  • Exclusion criteria linked to the product

研究组 & 干预措施

A

Experimental

50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)

干预措施: 50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar) (Drug)

B

Placebo Comparator

50% oxygen/50% Nitrogen premix

干预措施: 50% Oxygen/50% Nitrogen premix (Drug)

结局指标

主要结局

pain measurement with visual analogue scale

时间窗: EVA

次要结局

  • feasibility of the kalinox 170 bar in invasives gestures in oncology(opinion of the patent and the caregiver)
  • surveillance of the appearance of secondary effects(examination by the investigator)

研究者

发起方
Air Liquide Santé International
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
2 期
Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial SpondyloarthritisAxial Spondyloarthritis
NCT05445076Biocad250
已完成
3 期
A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/AzathioprineANCA Associated Vasculitis10047066
NL-OMON45712Chemocentryx6
已完成
不适用
A double-blind, multicentric, multinational randomised study to assess the effects of two years administration of 2 g per day of strontium ranelate versus bisphosphonate in women with postmenopausal osteoporosis on bone geometry and bone strength measured by peripheral-Quantitative Computed Tomography (p-QCT)Osteoporosis
ISRCTN10335153Institut de Recherches Internationales Servier (France)80
进行中(未招募)
不适用
An International, Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™, single oral 300 mg or 600 mg dose) and Lithium as Monotherapy in Adult Patients with Bipolar Depression for 8 weeks and Quetiapine in Continuation Treatment for 26 up to 52 weeks. - EMBOLDEN I
EUCTR2004-004681-33-DEAstraZeneca AB672
进行中(未招募)
不适用
An International, Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™, single oral 300 mg or 600 mg dose) and Lithium as Monotherapy in Adult Patients with Bipolar Depression for 8 weeks and Quetiapine in Continuation Treatment for 26 up to 52 weeks.Bipolar Depression
EUCTR2004-004681-33-LVAstraZeneca AB672